Form 4: Director Jason Hsu Receives Equity Grant in Immix Biopharma

Director Jason Hsu was granted 6,250 restricted stock units and 12,500 stock options as part of the company's 2021 Equity Incentive Plan.

Summary

• Director Jason Hsu acquired 6,250 restricted stock units (RSUs) on May 22, 2026.
• Director Jason Hsu was granted 12,500 stock options with an exercise price of $8.78 per share.
• The RSUs vest on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting.
• The stock options vest in equal monthly installments over 12 months, subject to continued service.
• Following these transactions, the director holds 899,250 shares directly and maintains indirect interests in 3,965,913 shares through affiliated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key board leadership through structured vesting schedules.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of stock options and vesting of RSUs.

Risks

• Vesting is contingent upon the director's continued service to the company.
• Market price volatility may impact the future value of the granted equity.

Future Outlook

The equity grants are subject to standard vesting conditions tied to the director's continued service and the timing of the 2027 Annual Meeting.

Management Comments

• The grants were issued pursuant to the Issuer's 2021 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector, intended to align director incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of 12-month vesting schedules for director equity is consistent with standard practices for small-cap biopharmaceutical companies.
• The structure of the grant aligns with typical compensation packages for independent directors in the life sciences industry.

Corporate Governance

Related Party Transactions

• The reporting person holds indirect interests through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of RSUs on the earlier of the one-year anniversary or the 2027 Annual Meeting.
• Monthly vesting of stock options over the next 12 months.

Key Dates

Keywords

Immix Biopharma, IMMX, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation